<?xml version="1.0" encoding="utf-8"?>
<Label drug="edarbi" setid="75b16bfc-38c1-4133-bd7d-13258d54edec">
<Text><Section name="Boxed Warning section" id="34066-1">
WARNING: FETAL TOXICITY 

 When pregnancy is detected, discontinue Edarbi as soon as possible [see Warnings and Precautions (5.1) ]. 

 Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see 

 Warnings and Precautions (5.1) 
 ]. 

 WARNING: FETAL TOXICITY 
 See full prescribing information for complete boxed warning. 

 • 
 When pregnancy is detected, discontinue Edarbi as soon as possible. ( 5.1 ) 

 • 
 Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 )</Section>
<Section name="DOSAGE &amp; ADMINISTRATION SECTION" id="34068-7">
2 DOSAGE AND ADMINISTRATION 

 The recommended dose in adults is 80 mg taken once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. ( 2.1 ) 
 Edarbi may be administered with or without food. ( 2.1 ) 
 Edarbi may be administered with other antihypertensive agents. ( 2.1 ) 

 2.1 Recommended Dose 

 The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics. 
 If blood pressure is not controlled with Edarbi alone, additional blood pressure reduction can be achieved by taking Edarbi with other antihypertensive agents. 
 Edarbi may be taken with or without food [see Clinical Pharmacology (12.3) ] . 

 2.2 Handling Instructions 

 Do not repackage Edarbi. Dispense and store Edarbi in its original container to protect Edarbi from light and moisture. 

 2.3 Special Populations 

 No initial dose adjustment is recommended for elderly patients, patients with mild-to-severe renal impairment, end-stage renal disease, or mild-to-moderate hepatic dysfunction. Edarbi has not been studied in patients with severe hepatic impairment [see Clinical Pharmacology (12.3) ] .</Section>
<Section name="CONTRAINDICATIONS SECTION" id="34070-3">
4 CONTRAINDICATIONS 

 Do not coadminister aliskiren with Edarbi in patients with diabetes 
 [see Drug Interactions (7)]. 

 Do not coadminister aliskiren with Edarbi in patients with diabetes. ( 4 )</Section>
<Section name="WARNINGS AND PRECAUTIONS SECTION" id="43685-7">
5 WARNINGS AND PRECAUTIONS 

 • Correct volume or salt depletion prior to administration of Edarbi. ( 5.2 ) 

 • Monitor for worsening renal function in patients with renal impairment. ( 5.3 ) 

 5.1 Fetal Toxicity 

 Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue Edarbi as soon as possible [see 

 Use in Specific Populations (8.1) 
 ]. 

 5.2 Hypotension in Volume- or Salt-Depleted Patients 

 In patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with Edarbi. Correct volume or salt depletion prior to administration of Edarbi, or start treatment at 40 mg. If hypotension does occur, the patient should be placed in the supine position and, if necessary, given an intravenous infusion of normal saline . A transient hypotensive response is not a contraindication to further treatment, which usually can be continued without difficulty once the blood pressure has stabilized. 

 5.3 Impaired Renal Function 

 As a consequence of inhibiting the renin-angiotensin system, changes in renal function may be anticipated in susceptible individuals treated with Edarbi. In patients whose renal function may depend on the activity of the renin-angiotensin system (e.g., patients with severe congestive heart failure, renal artery stenosis, or volume depletion), treatment with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers has been associated with oliguria or progressive azotemia and rarely with acute renal failure and death. Similar results may be anticipated in patients treated with Edarbi [see Drug Interactions (7) , Use in Specific Populations (8.6) 
 , and Clinical Pharmacology (12.3) ]. 

 In studies of ACE inhibitors in patients with unilateral or bilateral renal artery stenosis, increases in serum creatinine or blood urea nitrogen have been reported. There has been no long-term use of Edarbi in patients with unilateral or bilateral renal artery stenosis, but similar results may be expected.</Section>
<Section name="DRUG INTERACTIONS SECTION" id="34073-7">
7 DRUG INTERACTIONS 

 No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine, antacids, chlorthalidone, digoxin, fluconazole, glyburide, ketoconazole, metformin, pioglitazone, and warfarin. Therefore, Edarbi may be used concomitantly with these medications . 

 Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) 

 In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving azilsartan and NSAID therapy. 
 The antihypertensive effect of angiotensin II receptor antagonists, including azilsartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors. 

 Dual Blockade of the Renin-Angiotensin System (RAS) 

 Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on Edarbi and other agents that affect the RAS. 
 Do not coadminister aliskiren with Edarbi in patients with diabetes. Avoid use of aliskiren with Edarbi in patients with renal impairment (GFR &lt;60 mL/min). 

 Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia. ( 7 )</Section>
</Text><Sentences>
<Sentence id="351" LabelDrug="edarbi" section="34068-7">
<SentenceText>Edarbi may be administered with other antihypertensive agents .</SentenceText>
</Sentence>
<Sentence id="352" LabelDrug="edarbi" section="34068-7">
<SentenceText>If blood pressure is not controlled with Edarbi alone , additional blood pressure reduction can be achieved by taking Edarbi with other antihypertensive agents .</SentenceText>
</Sentence>
<Sentence id="353" LabelDrug="edarbi" section="34070-3">
<SentenceText>Do not coadminister aliskiren with Edarbi in patients with diabetes .</SentenceText>
<Mention id="M1" type="Trigger" span="0 19" str="Do not coadminister"/>
<Mention id="M2" type="Precipitant" span="20 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I1" type="Unspecified interaction" trigger="M1" precipitant="M2"/>
</Sentence>
<Sentence id="354" LabelDrug="edarbi" section="34070-3">
<SentenceText>Do not coadminister aliskiren with Edarbi in patients with diabetes see Drug Interactions ( 7 ) .</SentenceText>
<Mention id="M3" type="Trigger" span="0 19" str="Do not coadminister"/>
<Mention id="M4" type="Precipitant" span="20 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I2" type="Unspecified interaction" trigger="M3" precipitant="M4"/>
</Sentence>
<Sentence id="355" LabelDrug="edarbi" section="34073-7">
<SentenceText>Avoid use of aliskiren with Edarbi in patients with renal impairment ( GFR 60 mL/min ) .</SentenceText>
<Mention id="M5" type="Trigger" span="0 5" str="Avoid"/>
<Mention id="M6" type="Precipitant" span="13 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I3" type="Unspecified interaction" trigger="M5" precipitant="M6"/>
</Sentence>
<Sentence id="356" LabelDrug="edarbi" section="34073-7">
<SentenceText>Closely monitor blood pressure , renal function and electrolytes in patients on Edarbi and other agents that affect the RAS .</SentenceText>
<Mention id="M7" type="Trigger" span="8 7" str="monitor"/>
<Mention id="M8" type="Precipitant" span="97 26" str="agents that affect the RAS" code="NO MAP"/>
<Interaction id="I4" type="Unspecified interaction" trigger="M7" precipitant="M8"/>
</Sentence>
<Sentence id="357" LabelDrug="edarbi" section="34073-7">
<SentenceText>Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M15" type="Trigger" span="161 15" str="increased risks"/>
<Mention id="M10" type="Precipitant" span="113 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M17" type="SpecificInteraction" span="180 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M18" type="SpecificInteraction" span="193 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M19" type="SpecificInteraction" span="211 25" str=" changes in renal function " code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M20" type="SpecificInteraction" span="248 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M16" type="Precipitant" span="132 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I5" type="Pharmacodynamic interaction" trigger="M15" precipitant="M10" effect="M17;M18;M19;M20"/>
<Interaction id="I6" type="Pharmacodynamic interaction" trigger="M15" precipitant="M16" effect="M17;M18;M19;M20"/>
</Sentence>
<Sentence id="357" LabelDrug="edarbi" section="34073-7">
<SentenceText>Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.</SentenceText>
<Mention id="M27" type="Trigger" span="161 15" str="increased risks"/>
<Mention id="M22" type="Precipitant" span="113 14" str="ACE inhibitors" code="N0000029130"/>
<Mention id="M29" type="SpecificInteraction" span="180 11" str="hypotension " code="45007003: Low blood pressure (disorder)"/>
<Mention id="M30" type="SpecificInteraction" span="193 12" str=" hyperkalemia " code=" 14140009: Hyperkalemia (disorder)"/>
<Mention id="M31" type="SpecificInteraction" span="211 25" str=" changes in renal function " code=" 39539005: Abnormal renal function (finding)"/>
<Mention id="M32" type="SpecificInteraction" span="248 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M28" type="Precipitant" span="132 9" str="aliskiren" code="N0000176084"/>
<Interaction id="I7" type="Pharmacodynamic interaction" trigger="M27" precipitant="M22" effect="M29;M30;M31;M32"/>
<Interaction id="I8" type="Pharmacodynamic interaction" trigger="M27" precipitant="M28" effect="M29;M30;M31;M32"/>
</Sentence>
<Sentence id="358" LabelDrug="edarbi" section="34073-7">
<SentenceText>Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia.</SentenceText>
</Sentence>
<Sentence id="359" LabelDrug="edarbi" section="34073-7">
<SentenceText>In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or who have compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with angiotensin II receptor antagonists , including azilsartan , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M37" type="Trigger" span="263 10" str="may result"/>
<Mention id="M34" type="Precipitant" span="149 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M39" type="SpecificInteraction" span="277 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M40" type="SpecificInteraction" span="330 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M38" type="Precipitant" span="168 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I9" type="Pharmacodynamic interaction" trigger="M37" precipitant="M34" effect="M39;M40"/>
<Interaction id="I10" type="Pharmacodynamic interaction" trigger="M37" precipitant="M38" effect="M39;M40"/>
</Sentence>
<Sentence id="359" LabelDrug="edarbi" section="34073-7">
<SentenceText>In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or who have compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with angiotensin II receptor antagonists , including azilsartan , may result in deterioration of renal function , including possible acute renal failure .</SentenceText>
<Mention id="M45" type="Trigger" span="263 10" str="may result"/>
<Mention id="M42" type="Precipitant" span="149 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M47" type="SpecificInteraction" span="277 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M48" type="SpecificInteraction" span="330 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M46" type="Precipitant" span="168 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I11" type="Pharmacodynamic interaction" trigger="M45" precipitant="M42" effect="M47;M48"/>
<Interaction id="I12" type="Pharmacodynamic interaction" trigger="M45" precipitant="M46" effect="M47;M48"/>
</Sentence>
<Sentence id="360" LabelDrug="edarbi" section="34073-7">
<SentenceText>Monitor renal function periodically in patients receiving azilsartan and NSAID therapy .</SentenceText>
<Mention id="M49" type="Trigger" span="0 7" str="Monitor"/>
<Mention id="M50" type="Precipitant" span="73 5" str="NSAID" code="N0000175722"/>
<Interaction id="I13" type="Unspecified interaction" trigger="M49" precipitant="M50"/>
</Sentence>
<Sentence id="361" LabelDrug="edarbi" section="34073-7">
<SentenceText>No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine , antacids , chlorthalidone , digoxin , fluconazole , glyburide , ketoconazole , metformin , pioglitazone , and warfarin .</SentenceText>
</Sentence>
<Sentence id="362" LabelDrug="edarbi" section="34073-7">
<SentenceText>Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M63" type="Trigger" span="361 10" str="may result"/>
<Mention id="M52" type="Precipitant" span="89 16" str="COX-2 Inhibitors" code="n0000008288"/>
<Mention id="M65" type="SpecificInteraction" span="375 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M66" type="SpecificInteraction" span="427 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M56" type="Precipitant" span="0 38" str="Non-steroidal Anti-Inflammatory Agents" code="n0000175722"/>
<Mention id="M60" type="Precipitant" span="251 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M64" type="Precipitant" span="50 37" str="Selective Cyclooxygenase-2 Inhibitors" code="n0000008288"/>
<Interaction id="I14" type="Pharmacodynamic interaction" trigger="M63" precipitant="M52" effect="M65;M66"/>
<Interaction id="I15" type="Pharmacodynamic interaction" trigger="M63" precipitant="M56" effect="M65;M66"/>
<Interaction id="I16" type="Pharmacodynamic interaction" trigger="M63" precipitant="M60" effect="M65;M66"/>
<Interaction id="I17" type="Pharmacodynamic interaction" trigger="M63" precipitant="M64" effect="M65;M66"/>
</Sentence>
<Sentence id="362" LabelDrug="edarbi" section="34073-7">
<SentenceText>Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M79" type="Trigger" span="361 10" str="may result"/>
<Mention id="M68" type="Precipitant" span="89 16" str="COX-2 Inhibitors" code="n0000008288"/>
<Mention id="M81" type="SpecificInteraction" span="375 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M82" type="SpecificInteraction" span="427 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M72" type="Precipitant" span="0 38" str="Non-steroidal Anti-Inflammatory Agents" code="n0000175722"/>
<Mention id="M76" type="Precipitant" span="251 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M80" type="Precipitant" span="50 37" str="Selective Cyclooxygenase-2 Inhibitors" code="n0000008288"/>
<Interaction id="I18" type="Pharmacodynamic interaction" trigger="M79" precipitant="M68" effect="M81;M82"/>
<Interaction id="I19" type="Pharmacodynamic interaction" trigger="M79" precipitant="M72" effect="M81;M82"/>
<Interaction id="I20" type="Pharmacodynamic interaction" trigger="M79" precipitant="M76" effect="M81;M82"/>
<Interaction id="I21" type="Pharmacodynamic interaction" trigger="M79" precipitant="M80" effect="M81;M82"/>
</Sentence>
<Sentence id="362" LabelDrug="edarbi" section="34073-7">
<SentenceText>Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M95" type="Trigger" span="361 10" str="may result"/>
<Mention id="M84" type="Precipitant" span="89 16" str="COX-2 Inhibitors" code="n0000008288"/>
<Mention id="M97" type="SpecificInteraction" span="375 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M98" type="SpecificInteraction" span="427 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M88" type="Precipitant" span="0 38" str="Non-steroidal Anti-Inflammatory Agents" code="n0000175722"/>
<Mention id="M92" type="Precipitant" span="251 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M96" type="Precipitant" span="50 37" str="Selective Cyclooxygenase-2 Inhibitors" code="n0000008288"/>
<Interaction id="I22" type="Pharmacodynamic interaction" trigger="M95" precipitant="M84" effect="M97;M98"/>
<Interaction id="I23" type="Pharmacodynamic interaction" trigger="M95" precipitant="M88" effect="M97;M98"/>
<Interaction id="I24" type="Pharmacodynamic interaction" trigger="M95" precipitant="M92" effect="M97;M98"/>
<Interaction id="I25" type="Pharmacodynamic interaction" trigger="M95" precipitant="M96" effect="M97;M98"/>
</Sentence>
<Sentence id="362" LabelDrug="edarbi" section="34073-7">
<SentenceText>Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.</SentenceText>
<Mention id="M111" type="Trigger" span="361 10" str="may result"/>
<Mention id="M100" type="Precipitant" span="89 16" str="COX-2 Inhibitors" code="n0000008288"/>
<Mention id="M113" type="SpecificInteraction" span="375 31" str="deterioration of renal function " code="314983004: Deteriorating renal function (finding)"/>
<Mention id="M114" type="SpecificInteraction" span="427 19" str=" acute renal failure" code=" 14669001: Acute renal failure syndrome (disorder)"/>
<Mention id="M104" type="Precipitant" span="0 38" str="Non-steroidal Anti-Inflammatory Agents" code="n0000175722"/>
<Mention id="M108" type="Precipitant" span="251 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M112" type="Precipitant" span="50 37" str="Selective Cyclooxygenase-2 Inhibitors" code="n0000008288"/>
<Interaction id="I26" type="Pharmacodynamic interaction" trigger="M111" precipitant="M100" effect="M113;M114"/>
<Interaction id="I27" type="Pharmacodynamic interaction" trigger="M111" precipitant="M104" effect="M113;M114"/>
<Interaction id="I28" type="Pharmacodynamic interaction" trigger="M111" precipitant="M108" effect="M113;M114"/>
<Interaction id="I29" type="Pharmacodynamic interaction" trigger="M111" precipitant="M112" effect="M113;M114"/>
</Sentence>
<Sentence id="363" LabelDrug="edarbi" section="34073-7">
<SentenceText>The antihypertensive effect of angiotensin II receptor antagonists , including azilsartan , may be attenuated by NSAIDs , including selective COX-2 inhibitors .</SentenceText>
<Mention id="M118" type="Trigger" span="21 6;99 10" str="effect | attenuated"/>
<Mention id="M116" type="Precipitant" span="113 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M120" type="SpecificInteraction" span="4 23;99 10" str="antihypertensive effect | attenuated" code="NO MAP"/>
<Mention id="M119" type="Precipitant" span="132 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I30" type="Pharmacodynamic interaction" trigger="M118" precipitant="M116" effect="M120"/>
<Interaction id="I31" type="Pharmacodynamic interaction" trigger="M118" precipitant="M119" effect="M120"/>
</Sentence>
<Sentence id="363" LabelDrug="edarbi" section="34073-7">
<SentenceText>The antihypertensive effect of angiotensin II receptor antagonists , including azilsartan , may be attenuated by NSAIDs , including selective COX-2 inhibitors .</SentenceText>
<Mention id="M124" type="Trigger" span="21 6;99 10" str="effect | attenuated"/>
<Mention id="M122" type="Precipitant" span="113 6" str="NSAIDs" code="N0000175722"/>
<Mention id="M126" type="SpecificInteraction" span="4 23;99 10" str="antihypertensive effect | attenuated" code="NO MAP"/>
<Mention id="M125" type="Precipitant" span="132 26" str="selective COX-2 inhibitors" code="n0000008288"/>
<Interaction id="I32" type="Pharmacodynamic interaction" trigger="M124" precipitant="M122" effect="M126"/>
<Interaction id="I33" type="Pharmacodynamic interaction" trigger="M124" precipitant="M125" effect="M126"/>
</Sentence>
<Sentence id="364" LabelDrug="edarbi" section="34073-7">
<SentenceText>Therefore, Edarbi may be used concomitantly with these medications.</SentenceText>
</Sentence>
<Sentence id="365" LabelDrug="edarbi" section="43685-7">
<SentenceText>In patients with an activated renin-angiotensin system , such as volume - and/or salt-depleted patients ( e.g. , those being treated with high doses of diuretics ) , symptomatic hypotension may occur after initiation of treatment with Edarbi .</SentenceText>
</Sentence>
</Sentences>
<LabelInteractions><LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="aliskiren" precipitantCode="N0000176084" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Unspecified interaction" precipitant="aliskiren" precipitantCode="N0000176084"/>
<LabelInteraction type="Unspecified interaction" precipitant="agents that affect the ras" precipitantCode="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 14140009: Hyperkalemia (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect=" 39539005: Abnormal renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="ace inhibitors" precipitantCode="N0000029130" effect="45007003: Low blood pressure (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="nsaids" precipitantCode="N0000175722" effect="NO MAP"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cox-2 inhibitors" precipitantCode="n0000008288" effect="NO MAP"/>
<LabelInteraction type="Unspecified interaction" precipitant="nsaid" precipitantCode="N0000175722"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cox-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="cox-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="non-steroidal anti-inflammatory agents" precipitantCode="n0000175722" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="non-steroidal anti-inflammatory agents" precipitantCode="n0000175722" effect="314983004: Deteriorating renal function (finding)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cyclooxygenase-2 inhibitors" precipitantCode="n0000008288" effect=" 14669001: Acute renal failure syndrome (disorder)"/>
<LabelInteraction type="Pharmacodynamic interaction" precipitant="selective cyclooxygenase-2 inhibitors" precipitantCode="n0000008288" effect="314983004: Deteriorating renal function (finding)"/>

</LabelInteractions></Label>